Updates are available Correction dated 2020-11-02

Article History

Received: 2 April 2020

Accepted: 4 September 2020

First Online: 23 September 2020

Change Date: 2 November 2020

Change Type: Correction

Change Details: In the Original publication of the article, the authors found an error in the “Results” section under the heading “Abstract”. The corrected text is given below.

Compliance with ethical standards

:

: G.K., T.S., Y.U., M.T., and S.K. are employees of Asahi Kasei Pharma. G.K., T.S., and Y.U. have a patent pending (2018–183447) with Asahi Kasei Pharma. Y.S., M.A., and I.H. were members of the advisory board of this study. M.K. reports personal fees from Chugai Pharma, Yakult Honsha, Merck Serono, Takeda Pharma, Taiho Pharmaceutical, and Eli Lilly Japan, outside the submitted work. Y.S. reports personal fees from Pfizer, Shionogi, Daiichi Sankyo, Nipponzoki, Kyowakirin, Ayumi-Pharma, Hisamitsu, Japan Vaccine, Bikken, GSK, Tsumura, Terumo, Astra-Zeneca, Maruishi, Ono Pharma, Aspen, Nestle, and Japan Blood Product, outside the submitted work. T.K. reports personal fees from Chugai Pharma, Takeda Pharma, Eli Lilly Japan, and Yakult Honsha, outside the submitted work. H.S. reports personal fees from Bayer, Bristol-Myers Squibb, Chugai Pharma, Daiichi Sankyo, Eli Lilly Japan, Merck Bio Pharma, MSD, Ono Pharma, Sanofi, Taiho Pharmaceutical, Takeda, and Yakult Honsha, outside the submitted work. A.M. reports personal fees from Eli Lilly Japan, Chugai Pharma, and Takeda, outside the submitted work. Y.T. reports personal fees from Bayer, Merck Serono, Eli Lilly Japan, Chugai Pharma, Taiho Pharmaceutical, Ono Pharma, Takeda Pharma, Medicon, and Sawai Pharmaceutical, outside the submitted work. K.S. reports personal fees from Chugai Pharma, Takeda Pharma, Mochida Pharmaceutical, Merck Biopharma, Taiho Pharmaceutical, Ono Pharma, Eisai, Shionogi, Eli Lilly Japan, Daiichi Sankyo, Nihonkayaku, Kyowakirin, and Bayer Yakuhin, outside the submitted work. T.F. reports grants and personal fees from Oncolys BioPharma, outside the submitted work. T.M. reports personal fees from Chugai Pharma, Mitsubishi Tanabe Pharma, Miyarisan Pharmaceutical, EA Pharma, AbbVie GK, Kyorin Pharmaceutical, and Sanofi K.K., and other support from Kinshukai Medical, outside the submitted work. Y.H., N.N., and N.K. have nothing to disclose. M.A. reports grants from Kyowa Kirin, outside the submitted work. I.H. reports grants and personal fees from Chugai Pharma, Taiho Pharma, Daiichi Sankyo, Yakult Honsha, and Ono Pharma, outside the submitted work.

: All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards and with Good Clinical Practice guidelines. The protocol of this study was approved by the institutional review board of each participating site.

: Informed consent was obtained from all individual participants included in this study.